MSSP ACOs Using Milliman MedInsight Achieved Over $274M Shared Savings in 2022 Under CMS Medicare Shared Savings Program
SEATTLE, Nov. 17, 2023 /PRNewswire/ -- Milliman MedInsight, a leading healthcare data and analytics company, is pleased to announce the outstanding achievements of Accountable Care Organizations (ACOs) utilizing the Milliman MedInsight healthcare analytics platform in support of the Medicare Shared Savings Program (MSSP) for the 2022 performance year.
Key Highlights of 2022 Performance Results for Milliman MedInsight clients:
The Centers for Medicare & Medicaid Services (CMS) announced the 2022 MSSP savings in August, marking the sixth consecutive year of program savings, as reported by CMS. To participate in MSSP, providers must be affiliated with accountable care organizations (ACOs), which aim to decrease unnecessary healthcare expenses and foster cooperation among local physicians, hospitals, and providers to enhance patient care. The primary focus of ACOs is to improve quality of care, affordability, and overall patient experience.
Overall, the program's goal is to encourage healthcare providers to collaborate and coordinate care for Medicare beneficiaries, working towards reducing healthcare costs and improving quality of care.
As a pioneer in enterprise data management in healthcare, Milliman MedInsight is one of the healthcare industry's most highly regarded platforms for value-based care analytics. Since its inception in 1997, Milliman MedInsight has played a pivotal role in bridging the gap between cost management and care management. The platform supports actuarial, care, and data analytics teams with data warehousing, advanced analytics, prescriptive reporting, and tailored benchmarks.
To learn more about Milliman MedInsight, visit medinsight.com.
About Milliman MedInsight
View original content to download multimedia:https://www.prnewswire.com/news-releases/mssp-acos-using-milliman-medinsight-achieved-over-274m-shared-savings-in-2022-under-cms-medicare-shared-savings-program-301991452.html
SOURCE Milliman MedInsight